Patents by Inventor Herbert Gritsch
Herbert Gritsch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220389479Abstract: The present invention provides a heparin-insensitive assay for measuring the quantity of Factor XIa in a sample. The present invention provides a method for measuring the concentration of Factor XIa in a plasma sample by using enzymatic heparin degradation as sample pretreatment step.Type: ApplicationFiled: October 9, 2020Publication date: December 8, 2022Inventors: Herbert Gritsch, Magdalena Schlager, Alfred Weber
-
Publication number: 20170227557Abstract: The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition.Type: ApplicationFiled: January 16, 2017Publication date: August 10, 2017Inventors: Peter Turecek, Juergen Siekmann, Alfred Weber, Herbert Gritsch, Katalin Varadi, Susanne Vejda
-
Patent number: 9547016Abstract: The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition.Type: GrantFiled: September 13, 2013Date of Patent: January 17, 2017Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Peter Turecek, Juergen Siekmann, Alfred Weber, Herbert Gritsch, Katalin Varadi, Susanne Vejda
-
Patent number: 9493544Abstract: The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.Type: GrantFiled: September 14, 2012Date of Patent: November 15, 2016Assignees: Nektar Therapeutics, Baxalta Incorporated, Baxalta GmbHInventors: Mary J. Bossard, Gayle Stephenson, Zhihao Fang, Harold Zappe, Stacy Mitchell, Ping Zhang, Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann, Katalin Varadi, Herbert Gritsch
-
Publication number: 20140051094Abstract: The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition.Type: ApplicationFiled: September 13, 2013Publication date: February 20, 2014Applicants: Baxter Healthcare SA, Baxter International Inc.Inventors: Peter Turecek, Juergen Siekmann, Alfred Weber, Herbert Gritsch, Katalin Varadi, Susanne Vejda
-
Patent number: 8557534Abstract: The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition.Type: GrantFiled: December 23, 2008Date of Patent: October 15, 2013Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Juergen Siekmann, Alfred Weber, Herbert Gritsch, Katalin Varadi, Susanne Vejda
-
Publication number: 20130012442Abstract: The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicants: NEKTAR THERAPEUTICS, Baxter Healthcare SA, Baxter International Inc.Inventors: Mary J. Bossard, Gayle Stephenson, Zhihao Fang, Harold Zappe, Stacy Mitchell, Ping Zhang, Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann, Katalin Varadi, Herbert Gritsch
-
Patent number: 8349800Abstract: The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.Type: GrantFiled: February 10, 2012Date of Patent: January 8, 2013Assignees: Nektar Therapeutics, Baxter International Inc., Baxter Healthcare S.A.Inventors: Mary J. Bossard, Gayle Stephenson, Zhihao Fang, Harold Zappe, Stacy Mitchell, Ping Zhang, Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann, Katalin Varadi, Herbert Gritsch
-
Publication number: 20120142594Abstract: The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.Type: ApplicationFiled: February 10, 2012Publication date: June 7, 2012Applicants: Baxter International Inc., NEKTAR THERAPEUTICSInventors: Mary J. Bossard, Gayle Stephenson, Zhihao Fang, Harold Zappe, Stacy Mitchell, Ping Zhang, Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann, Katalin Varadi, Herbert Gritsch
-
Patent number: 8133865Abstract: The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.Type: GrantFiled: December 27, 2007Date of Patent: March 13, 2012Assignees: Nektar Therapeutics, Baxter International Inc., Baxter Healthcare S.A.Inventors: Mary J. Bossard, Gayle Stephenson, Zhihao Fang, Harold Zappe, Stacy Mitchell, Ping Zhang, Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann, Katalin Varadi, Herbert Gritsch
-
Patent number: 8053561Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule having at least a portion of the B domain intact, which is conjugated to a water-soluble polymer such as polyethylene glycol having a molecular weight of greater than 10,000 Daltons. The construct has a biological activity of at least 80% of the biological activity of native Factor VIII, and the in vivo half-life of the construct is increased by at least 1.5 fold as compared to the in vivo half-life of native factor FVIII.Type: GrantFiled: March 8, 2010Date of Patent: November 8, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Juergen Siekmann, Katalin Varadi, Herbert Gritsch, Peter Turecek
-
Publication number: 20110072524Abstract: The present invention relates, generally, to a transgenic non-human animal model of hemophilia A, wherein the transgenic animal is deficient in endogenous Factor VIII and endogenous von Willebrand Factor, and methods to treat hereditary or acquired hemophilia A or von Willebrand Disease (VWD) by administration of exogenous human VWF.Type: ApplicationFiled: August 4, 2010Publication date: March 24, 2011Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: Peter Turecek, Raffi Udin Ahmad, Herbert Gritsch, Eva-Maria Muchitsch, Hans-Peter Schwarz
-
Publication number: 20100168391Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule having at least a portion of the B domain intact, which is conjugated to a water-soluble polymer such as polyethylene glycol having a molecular weight of greater than 10,000 Daltons. The construct has a biological activity of at least 80% of the biological activity of native Factor VIII, and the in vivo half-life of the construct is increased by at least 1.5 fold as compared to the in vivo half-life of native factor FVIII.Type: ApplicationFiled: March 8, 2010Publication date: July 1, 2010Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: Juergen Siekmann, Katalin Varadi, Herbert Gritsch, Peter Turecek
-
Patent number: 7683158Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule having at least a portion of the B domain intact, which is conjugated to a water-soluble polymer such as polyethylene glycol having a molecular weight of greater than 10,000 Daltons. The construct has a biological activity of at least 80% of the biological activity of native Factor VIII, and the in vivo half-life of the construct is increased by at least 1.5 fold as compared to the in vivo half-life of native factor FVIII.Type: GrantFiled: March 29, 2007Date of Patent: March 23, 2010Assignees: Baxter International Inc., Baxter HealthcareInventors: Juergen Siekmann, Katalin Varadi, Herbert Gritsch, Peter Turecek
-
Publication number: 20090220993Abstract: The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition.Type: ApplicationFiled: December 23, 2008Publication date: September 3, 2009Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: Peter Turecek, Juergen Siekmann, Alfred Weber, Herbert Gritsch, Katalin Varadi, Susanne Vejda
-
Publication number: 20080234193Abstract: The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.Type: ApplicationFiled: December 27, 2007Publication date: September 25, 2008Applicants: Nektar Therapeutics AL, Corporation, Baxter International Inc., Baxter Healthcare SAInventors: Mary J. Bossard, Gayle Stephenson, Zhihao Fang, Harold Zappe, Stacy Mitchell, Ping Zhang, Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann, Katalin Varadi, Herbert Gritsch
-
Publication number: 20070244301Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule having at least a portion of the B domain intact, which is conjugated to a water-soluble polymer such as polyethylene glycol having a molecular weight of greater than 10,000 Daltons. The construct has a biological activity of at least 80% of the biological activity of native Factor VIII, and the in vivo half-life of the construct is increased by at least 1.5 fold as compared to the in vivo half-life of native factor FVIII.Type: ApplicationFiled: March 29, 2007Publication date: October 18, 2007Inventors: Juergen Siekmann, Katalin Varadi, Herbert Gritsch, Peter Turecek
-
Patent number: 5410022Abstract: The invention relates to a method of producing virus-safe highly purified factor VIII. The method includes a combination of the following measures:a) chromatographic purification of a factor VIII-containing fraction,b) tenside treatment of factor VIII in an aqueous solution at a tenside/protein ratio of from 1:1 to 1000:1, andc) heat treatment of the factor VIII preparation in the solid state.Type: GrantFiled: April 20, 1993Date of Patent: April 25, 1995Assignee: Immuno AktiengesellschaftInventors: Johann Eibl, Friedrich Elsinger, Herbert Gritsch, Yendra Linnau, Otto Schwarz, Peter Turecek, Gunther Wober
-
Patent number: 4561076Abstract: A method and apparatus for underwater ranging with the aid of sonic pulses, by irradiating a given transmitting area with sonic energy pulses from a transmitter mounted in a marine vessel, receiving sonic energy echoes reflected from bodies in the transmitting area in a manner which is selective with respect to direction in a plurality of receiving sectors arranged in a fan shape, and associating the received echoes with respective reflection centers within the respective receiving sectors on the basis of associated sonic pulse travel times. Reception is carried out on a second marine vessel different from the vessel carrying the transmitter and which travels at a rearward offset position from the vessel carrying the transmitter at such a distance therefrom that the receiving sectors cover at least part of the given transmitting area, and the azimuthal width of the transmitting area is made very small.Type: GrantFiled: May 27, 1983Date of Patent: December 24, 1985Assignee: Fried. Krupp Gesellschaft mit beschrankter HaftungInventor: Herbert Gritsch